Life Healthcare Group Holdings Limited has announced the fulfillment of all Conditions Precedent for the disposal of its interests in Life Molecular Imaging to Lantheus Holdings Inc., as defined in their Sale and Purchase Agreement. The transaction is expected to conclude on 21 July 2025. Life Healthcare plans, pending board approval, to return the net proceeds from the upfront payment to shareholders within the next 12 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Life Healthcare Group Holdings Limited published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.